您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > EUK 134
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
EUK 134
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
EUK 134图片
CAS NO:81065-76-1
规格:≥98%
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议
1g电议

产品介绍
理化性质和储存条件
Molecular Weight (MW)416.74
FormulaC18H18ClMnN2O4
CAS No.81065-76-1
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 83 mg/mL (199.2 mM)
Water: 13 mg/mL (31.2 mM)
Ethanol: <1 mg/mL
SMILESCOC1=C2C(C=[N]3CC[N]4=CC5=CC=CC(OC)=C5O[Mn+3]34([O-2]2)[Cl-])=CC=C1
Synonyms EUK-134; EUK-134; EUK-134
实验参考方法
In Vitro

In vitro activity: EUK 134 shows potent catalase and SOD activities, and protects human fibroblasts against cytotoxicity by glucose and glucose oxidase. EUK 134 (20 μM) prevents Aβ-induced microglial proliferation in vitro. In SK-N-MC cells, EUK134 protects neuronal cells against H(2)O(2) toxicity by attenuating oxidative stress through inhibition of MAPK pathway, and also results in decreased expression of pro-apoptotic genes p53 and Bax as well as enhanced expression of anti-apoptotic Bcl-2 gene. EUK 134 significantly inhibits amyloid formation at two molar ratios of 1:1 and 5:1 (drugs to protein).


Cell Assay: in SK-N-MC cells, EUK134 protects neuronal cells against H2O2 toxicity by attenuating oxidative stress through inhibition of MAPK pathway, and also results in decreased expression of pro-apoptotic genes p53 and Bax as well as enhanced expression of anti-apoptotic Bcl-2 gene. Pretreatment with EUK-134 (10 μM) was effective in the prevention of hypertrophic changes in H9C2 cells, reduction of oxidative stress, and prevention of metabolic shift. EUK-134 treatment improved the oxidative status of mitochondria and reversed hypertrophy-induced reduction of mitochondrial membrane potential.

In VivoEUK 134 (2.5 mg/kg), in a middle cerebral artery occlusion model, significantly reduces brain infarct size, and apparently prevents further infarct growth. EUK-134 prevents oxidative stress and attenuates rat brain damage induced by systemic administration of systemic kainic acid (KA).
Animal modelRat model in stroke.
Formulation & DosageDissolved in 0.9% saline; 2.5 mg/kg; i.v. injection
ReferencesJ Pharmacol Exp Ther. 1998 Jan;284(1):215-21; Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9897-902.